Could boosting natural endocannabinoids help treat migraine pain?
Inhibiting the enzymes that break down endocannabinoids (MAGL and FAAH) could raise natural painkiller levels and offer a targeted approach to migraine without the psychoactive effects of cannabis.
Quick Facts
What This Study Found
MAGL and FAAH, the enzymes that degrade endocannabinoids, are distributed differently across brain regions involved in migraine pain. Blocking these enzymes raises levels of 2-AG and anandamide, which can reduce pain through both cannabinoid receptors and direct modulation of ion channels in pain neurons.
Key Numbers
Review covers two main enzyme targets (MAGL and FAAH) and two primary endocannabinoids (2-AG and anandamide) across multiple pain signaling pathways.
How They Did This
Thematic review synthesizing research on endocannabinoid degradation pathways, migraine pain signaling, and emerging enzyme inhibitors.
Why This Research Matters
Current migraine treatments have limited effectiveness. Targeting the endocannabinoid system through enzyme inhibition could provide pain relief without the side effects and psychoactivity of plant-derived cannabis.
The Bigger Picture
Because endocannabinoids are produced "on demand" at sites of pain signaling, boosting their levels through enzyme inhibition could provide more targeted pain relief than administering external cannabinoids.
What This Study Doesn't Tell Us
Much of the evidence comes from preclinical studies. Clinical trials of MAGL and FAAH inhibitors for migraine are still needed.
Questions This Raises
- ?Will MAGL and FAAH inhibitors prove safe and effective in human migraine trials?
- ?Could combining both types of inhibitors provide greater relief?
Trust & Context
- Key Stat:
- Two enzyme targets (MAGL and FAAH) could boost natural pain relief
- Evidence Grade:
- Thematic review of mostly preclinical research; clinical evidence for this approach in migraine is still lacking.
- Study Age:
- Published in 2022.
- Original Title:
- Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain.
- Published In:
- International journal of molecular sciences, 23(8) (2022)
- Authors:
- Della Pietra, Adriana(4), Savinainen, Juha(3), Giniatullin, Rashid(3)
- Database ID:
- RTHC-03798
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How is this different from using cannabis for migraine?
Instead of adding external cannabinoids, this approach raises the body's own endocannabinoid levels by blocking the enzymes that break them down, potentially providing targeted relief without psychoactive effects.
Are these enzyme inhibitors available as treatments?
Not yet for migraine. Potent MAGL and FAAH inhibitors have been developed, but clinical trials specifically for migraine pain are still needed.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03798APA
Della Pietra, Adriana; Savinainen, Juha; Giniatullin, Rashid. (2022). Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain.. International journal of molecular sciences, 23(8). https://doi.org/10.3390/ijms23084407
MLA
Della Pietra, Adriana, et al. "Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain.." International journal of molecular sciences, 2022. https://doi.org/10.3390/ijms23084407
RethinkTHC
RethinkTHC Research Database. "Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic ..." RTHC-03798. Retrieved from https://rethinkthc.com/research/della-2022-inhibiting-endocannabinoid-hydrolysis-as
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.